Progestagens in high-risk pregnancy. What we know today
Open Access
- 30 June 2023
- journal article
- research article
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 68,p. 22-28
Abstract
Miscarriage remains an important global problem: 23 million miscarriages are registered annually in the world, i.e. 44 pregnancy losses every minute, and the total risk of miscarriage is 15.3% of all pregnancies. Effective methods of pregnancy preservation (in case of idiopathic miscarriage and threatened miscarriage) include lifestyle modification and progestagen therapy. Progesterone is the main hormone necessary to maintain pregnancy. The effectiveness of progestogens among medical methods that increase the chances of pregnancy preservation has been proven by numerous studies. Effectiveness and safety of various types of progestogens during pregnancy have been studied. As a result, progesterone and dydrogesterone became the only progestogens approved for use in obstetrics – micronized progesterone and dydrogesterone reduce the frequency of miscarriage in women with clinical diagnoses of threatened miscarriage and idiopathic recurrent miscarriage. In addition, the progestogens safety has been carefully studied in modern randomized studies, prospective trials and meta-analyses and the same safety profile of dydrogesterone and micronized progesterone for pregnant women and the fetus has been proven. Studies have shown that oral dydrogesterone has relatively low antagonistic activity at glucocorticoid and mineralocorticoid receptors compared to progesterone and therefore well tolerated. Oral dydrogesterone due to the peculiarities of structure has improved bioavailability compared to progesterone, which allows a woman to avoid the inconvenience and discomfort associated with the intravaginal or intramuscular use of progesterone. In addition, dydrogesterone has a 1.5 times higher affinity for progesterone receptors compared to micronized progesterone and a pronounced anti-inflammatory and immunomodulation effect, which provides certain clinical advantages for patients after recurrent pregnancy losses. Thus, progestogens are indicated for all patients with recurrent pregnancy losses from the moment of receiving a positive pregnancy test, as they reduce the risk of miscarriage. It is important that the use of progestagen drugs during the first and second trimester of pregnancy is not associated with side effectsKeywords
This publication has 46 references indexed in Scilit:
- RETRACTED: Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trialFertility and Sterility, 2014
- Progesterone Pharmacokinetics and Pharmacodynamics With 3 Dosages and 2 Regimens of an Effervescent Micronized Progesterone Vaginal InsertThe Journal of Clinical Endocrinology & Metabolism, 2014
- Preparation of steroidal hormones with an emphasis on transformations of phytosterols and cholesterol - a reviewMediterranean Journal of Chemistry, 2014
- Progestogens Used in Postmenopausal Hormone Therapy: Differences in Their Pharmacological Properties, Intracellular Actions, and Clinical EffectsEndocrine Reviews, 2012
- Selectivity and potency of the retroprogesterone dydrogesterone in vitroSteroids, 2011
- Dydrogesterone in threatened miscarriage: A Malaysian experienceMaturitas, 2009
- The emotional burden of miscarriage for women and their partners: trajectories of anxiety and depression over 13 monthsBJOG: An International Journal of Obstetrics & Gynaecology, 2007
- Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriageHuman Reproduction, 2006
- A comparative molecular modeling study of dydrogesterone with other progestational agents through theoretical calculations and nuclear magnetic resonance spectroscopyThe Journal of Steroid Biochemistry and Molecular Biology, 2006
- Classification and pharmacology of progestinsMaturitas, 2003